Education, Science, Technology, Innovation and Life
Open Access
Sign In
  1. Home
  2. Journals
  3. MEDS Chinese Medicine
  4. Vol 6, Issue 3, 2024

Research progress on the prevention and treatment of chronic heart failure with integrated traditional Chinese and Western medicine

Download as PDF

DOI: 10.23977/medcm.2024.060302 | Downloads: 4 | Views: 200

Author(s)

Zhang Ning 1, Zhi Liqin 2

Affiliation(s)

1 Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China
2 Affiliated Hospital of Integrated Traditional and Western Medicine of Shaanxi University of Chinese Medicine, Xi'an, 710000, China (Xi'an No. 5 Hospital, Xi'an, 710000, China)

Corresponding Author

Zhi Liqin

ABSTRACT

Chronic heart failure (CHF) is a persistent state of heart failure, which is the severe and terminal stage of the development of a variety of heart diseases. It is particularly important to explore how to treat chronic heart failure more effectively, because of its severe disease, long course of disease, high mortality rate, reduced quality of life, and poor prognosis. In the collation of relevant literature on chronic heart failure, it was found that the combination of traditional Chinese and Western medicine has a good clinical effect. This article takes the combination of traditional Chinese and Western medicine in the treatment of chronic heart failure as the starting point, discusses its research progress, and provides more treatment methods and ideas for the clinical prevention and treatment of chronic heart failure.

KEYWORDS

Combination of Chinese and Western; chronic heart failure; Chinese medicine; Review

CITE THIS PAPER

Zhang Ning, Zhi Liqin, Research progress on the prevention and treatment of chronic heart failure with integrated traditional Chinese and Western medicine. MEDS Chinese Medicine (2024) Vol. 6: 12-17. DOI: http://dx.doi.org/10.23977/medcm.2024.060302.

REFERENCES

[1] Ashraf H, Rosenthal J L. Right Heart Failure: Causes and Clinical Epidemiology[J]. Cardiol Clin, 2020, 38(2): 175-183. 
[2] Gao Hai, Jin Yanyan. Analysis of domestic and foreign guidelines for chronic heart failure[J]. Chinese Clinician, 2014, 42(09):3-6. 
[3] Ma Liyuan, Wang Zengwu, Fan Jing, etc. . Key points of China Cardiovascular Health and Disease Report 2022[J]. Chinese general practice, 2023, 26(32): 3975-3994. 
[4] Groenewegen A, Rutten F H, Mosterd A, et al. Epidemiology of heart failure[J]. European journal of heart failure, 2020, 22(8):1342-1356. 
[5] Li L, Liu R, Jiang C, et al. Assessing the evidence–practice gap for heart failure in China: the Heart Failure Registry of Patient Outcomes (HERO) study design and baseline characteristics[J]. European Journal of Heart Failure, 2020, 22(4):646-660. 
[6] Wang Hua, Li Yingying. Interpretation of the 2022 AHA/ACC/HFSA guidelines for the management of heart failure: Classification and diagnostic evaluation of heart failure from the perspective of the new guidelines[J]. Chinese Journal of Cardiovascular Research, 2022, 20(06):481-486. 
[7] Niu Baoliang. Comparison of the effects of sacubitril-valsartan and enalapril in the treatment of elderly patients with heart failure with reduced ejection fraction[J]. China Minkang Medicine, 2024, 36(12):141-144. 
[8] Huo Jiaqi, Tian Houze, Chen Xinyu, et al. Efficacy of sacubitril-valsartan in the treatment of chronic heart failure and its effect on the levels of GAL-3 and IL-33[J]. Medical Theory & Practice, 2024, 37(12): 2016-2018. DOI:10. 19381/j. issn. 1001-7585. 2024. 12. 010. 
[9] Ji L, Xu Q, Cui Y, et al. Efficacy and safety of sacubitril-valsartan in the treatment of patients with end-stage renal disease complicated with heart failure[J]. Journal of Xinxiang Medical College, 2024, 41(04):333-337. 
[10] Zheng Bo, Fei Jintao, Huo Yong. ESC 2019 DAPA-HF Study: Cross-border Performance of SGLT2 Inhibitors[J]. Chinese Journal of Molecular Cardiology, 2020, 20(01):3193-3195. 
[11] Zelniker TA, Wiviott SD, Raz I, Im K, Goodrich EL, Bonaca MP, Mosenzon O, Kato ET, Cahn A, Furtado RHM, Bhatt DL, Leiter LA, McGuire DK, Wilding JPH, Sabatine MS. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet. 2019 Jan 5; 393(10166):31-39. doi: 10. 1016/S0140-6736(18)32590-X. Epub 2018 Nov 10. Erratum in: Lancet. 2019 Jan 5; 393(10166):30. doi: 10. 1016/S0140-6736(18)33206-9. PMID: 30424892. 
[12] Zhang Ban. Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure with preserved ejection fraction [D]. Huazhong University of Science and Technology, 2022. DOI:10. 27157/d. cnki. ghzku. 2022. 005527. 
[13] A P W A, B L R, C M J P, et al. A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of the Efficacy and Safety of the Oral Soluble Guanylate Cyclase Stimulator: The VICTORIA Trial – Science Direct[J]. JACC: Heart Failure, 2018, 6(2):96-104. 
[14] Jia Xiaoyan, An Jinyang, Peng Keling, et al. Network meta-analysis of the efficacy and safety of soluble guanylate cyclase agonists in the treatment of heart failure[J]. Chinese Journal of New Drugs and Clinical Medicine, 2023, 42(01):48-57. DOI:10. 14109/j. cnki. xyylc. 2023. 01. 10. 
[15] Zhou Zhongying, Jin Shi, Li Mingfu, et al. Internal Medicine of Traditional Chinese Medicine[J]. China Publishing House of Traditional Chinese Medicine, 2007. 
[16] Zhou Zhongying, Jin Miaowen, Wu Mianhua, Tang Decai, Zhou Ning. Clinical study on the treatment of congestive heart failure by invigorating yin and yang, invigorating blood and passing pulses[J]. Journal of Nanjing University of Traditional Chinese Medicine (Natural Science Edition), 2000(01):13-16. 
[17] Li Lizhi. Chen Keji's experience in the treatment of congestive heart failure[J]. Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 2006, 4(2):136-138. 
[18] Zhang Keqing, Li Xiangzhong. Professor Li Xiangzhong's academic experience in the treatment of chronic heart failure [J]. Bright Chinese Medicine, 2022, 37(21):3880-3882. 
[19] Zhang Jianjun. Aligning with International Guidelines and Highlighting Chinese Characteristics: Interpretation of the Chinese Guidelines for the Diagnosis and Treatment of Heart Failure 2018[J]. Chinese Journal of Clinical Doctors, 2019, 47(04):398-402. 
[20] Mao Jingyuan, Zhu Mingjun. Expert consensus on TCM diagnosis and treatment of chronic heart failure[J]. Journal of Traditional Chinese Medicine, 2014, 55(14):1258-1260. 
[21] Chen Keji, Wu Zonggui, Zhu Mingjun, et al. Expert consensus on the diagnosis and treatment of chronic heart failure with integrated traditional Chinese and Western medicine[J]. Journal of Prevention and Treatment of Cardiovascular and Cerebrovascular Diseases, 2016, 16(05):340-347. 
[22] Wang Jianxin, Lin Jiangtao, Sun Zengtao, et al. Attaching importance to the standardized application of Chinese patent medicine in the prevention and treatment of asthma—Interpretation of the clinical application guidelines of Chinese patent medicine in the treatment of bronchial asthma 2021[J/OL]. Chinese Journal of Integrated Traditional and Western Medicine, 1-5[2024-07-08]. http://kns. cnki. net/kcms/detail/11. 2787. R. 20231101. 1701. 010. html. 
[23] Pan Jianluo, Li Menghan, Guo Weijian, et al. Network meta-analysis of the efficacy of traditional Chinese medicine injection in the treatment of heart failure with preserved ejection fraction[J]. Journal of Cardiovascular and Cerebrovascular Diseases of Integrated Traditional Chinese and Western Medicine, 2023, 21(18):3281-3291+3297. 
[24] Li Zhichao, Huang Wentong, Li Wen, et al. Effect of Shenfu injection combined with conventional western medicine on cardiac function, related inflammatory factors and BNP in patients with coronary heart disease and heart failure[J]. Yunnan Journal of Traditional Chinese Medicine, 2018, 39(10):26-28. DOI: 10. 16254/j. cnki. 53-1120/r. 2018. 10. 010. 
[25] Zheng Meihua. Effect analysis of Shengmaisan combined with sacubitril-valsartan sodium tablets in the treatment of chronic heart failure with decreased ejection fraction in qi and yin deficiency syndrome[J]. Knowledge of Prevention and Treatment of Cardiovascular Diseases, 2021, 11(22):12-14. 
[26] Tang Kanghui. Study on Zhenwu Tang Hewu Ling San in the treatment of Yang Deficiency Water Generalized Heart Failure [J]. Chinese Medicine Guide, 2024, 22(14):153-155. DOI:10. 15912/j. issn. 1671-8194. 2024. 14. 045. 
[27] Wu Fengzhu, Zhang Jiamei. Study on the clinical efficacy of acupuncture Neiguan acupoint in the treatment of chronic heart failure [J]. Journal of Practical Cardio-Cerebropulmonary and Vascular Diseases, 2020, 28(08):98-104.

Subscription
E-Mail Alert
Most popular papers
Call for Special Issue
Publication Ethics & OA Statement
Plagiarism Policy
Contact Us
Downloads: 5394
Visits: 241011

Sponsors, Associates, and Links

All published work is licensed under a Creative Commons Attribution 4.0 International License.

Copyright © 2016 - 2031 Clausius Scientific Press Inc. All Rights Reserved.